Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Daiichi Sankyo
Chubb
Boehringer Ingelheim
Express Scripts
Merck
Queensland Health
Colorcon
Chinese Patent Office

Generated: November 18, 2018

DrugPatentWatch Database Preview

MULTAQ Drug Profile

« Back to Dashboard

Which patents cover Multaq, and what generic alternatives are available?

Multaq is a drug marketed by Sanofi Aventis Us and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in MULTAQ is dronedarone hydrochloride. There are nineteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the dronedarone hydrochloride profile page.

Drug patent expirations by year for MULTAQ
Synonyms for MULTAQ
141625-93-6
2-n-butyl 3-[4-(3-di-n-butylamino-propoxy)benzoyl] 5-methylsulfonamido benzofuran hydrochloride
4CH-007232
AB2000517
AC-5011
AC1L55X4
AC1Q3EU3
AK-72887
AKOS005145691
AN-544
ANW-49035
BC201083
BR-72887
C31H44N2O5S.HCl
CD0187
CHEMBL1201729
CS-0712
CTK8B5527
D03914
D4689
Dronedarone HCl
Dronedarone (Hydrochloride)
Dronedarone HCl
Dronedarone HCl (Multaq)
Dronedarone hydrochloride
Dronedarone hydrochloride (USAN)
Dronedarone hydrochloride [USAN]
Dronedarone Hydrochloride 1.0 mg/ml in Methanol (as free base)
Dronedarone hydrochloride, >=98% (HPLC)
Dronedarone hydrochloride, United States Pharmacopeia (USP) Reference Standard
DRONEDARONEHYDROCHLORIDE
DTXSID30161779
DWKVCQXJYURSIQ-UHFFFAOYSA-N
FA36DV299Q
FT-0667799
HY-75839
J-007525
J-520429
KB-76727
KS-00000G47
KS-1260
MCULE-2160502046
Methanesulfonamide, N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-, monohydrochloride
MFCD00914940
MLS004774028
MLS006011986
MolPort-005-932-572
Multaq (TN)
multaq hydrochloride
N-(2-Butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide monohydrochloride
N-(2-Butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-benzofuran-5-yl)methanesulfonamide hydrochloride
N-(2-Butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)methanesulfonamide hydrochloride
N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride
N-(2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl)methanesulfonamide hydrochloride
N-[2-butyl-3-[4-(3-dibutyl-aminopropoxy) benzoyl] methanesulfonamide hydrochloride
N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide hydrochloride
N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide;hydrochloride
N-[2-Butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]methanesulfonamide Hydrochloride
N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]benzofuran-5-yl]methanesulfonamide hydrochloride
RL01735
RTC-070901
S-7529
s2114
SCHEMBL223035
SMR003500707
SR-33589B
SR-33598B
SR33598B
ST2413542
UNII-FA36DV299Q
W3083
Z1550675452

US Patents and Regulatory Information for MULTAQ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for MULTAQ

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for MULTAQ
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 400 mg ➤ Subscribe ➤ Sign Up

Supplementary Protection Certificates for MULTAQ

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00446 Netherlands ➤ Sign Up PRODUCT NAME: DRONEDARON, DESGEWENST IN DE VORM VAN EEN AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/09/591/001-004 20091126
C008/2010 Ireland ➤ Sign Up SPC008/2010: 20101015, EXPIRES: 20230616
673 Luxembourg ➤ Sign Up 91673, EXPIRES: 20230619
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Daiichi Sankyo
Chubb
Boehringer Ingelheim
Express Scripts
Merck
Queensland Health
Colorcon
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.